Why the study?
What are the pharmacokinetic properties of intravenous ouabain in dogs and humans?
Population
Dogs and normal human subjects
Design
Other
Follow-up
9 days
Authors
Loading...
Informs potential ouabain dosing intervals in humans; extends canine PK data yet leaves open validation in patients.
What are the pharmacokinetic properties of intravenous ouabain in dogs and humans?
The pharmacokinetic half-life of intravenous ouabain is approximately 21 hours in humans, correlating well with its clinical duration of action.
Selden et al. (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: